var data={"title":"Alendronate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Alendronate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5583?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=alendronate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Alendronate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=alendronate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Alendronate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131404\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Binosto;</li>\n      <li>Fosamax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131405\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fosamax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131424\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Bisphosphonate Derivative</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131408\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The optimal duration of osteoporosis treatment has not been determined. In postmenopausal women with low fracture risk, consider a drug holiday after 5 years of oral bisphosphonate therapy. In postmenopausal women who remain at high fracture risk, consider extending treatment for up to 10 years (AACE/ACE [Camacho 2016]; Adler 2016). Although evidence is limited, applying these recommendations to treatment duration in older men may be considered (Adler 2016). Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis in postmenopausal females:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prophylaxis: 5 mg once daily <b>or</b> 35 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment: 10 mg once daily <b>or</b> 70 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis in males:</b> Oral: Treatment: 10 mg once daily <b>or</b> 70 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis secondary to glucocorticoids in males and females:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Treatment: 5 mg once daily; a dose of 10 mg once daily should be used in postmenopausal females who are not receiving estrogen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prevention (off-label use): 5 mg once daily; a dose of 10 mg once daily should be used in postmenopausal females who are not receiving estrogen (Saag 1998). <b>Note</b>: Use is not recommended in women who are pregnant or who plan on becoming pregnant (ACR [Buckley 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Paget disease of bone in males and females:</b> Oral: 40 mg once daily for 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Re-treatment: Following a 6-month post-treatment evaluation period, treatment with alendronate may be considered in patients who have relapsed based on increases in serum alkaline phosphatase, which should be measured periodically. Re-treatment may also be considered in those who failed to normalize their serum alkaline phosphatase. The Endocrine Society guidelines suggest re-treatment may be required between 2 and 6 years (Singer 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed doses (once weekly):</i> If a once-weekly dose is missed, it should be given the next morning after remembered; may then return to the original once-weekly schedule (original scheduled day of the week), however, do not give 2 doses on the same day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteogenesis imperfecta (off-label use):</b> Oral: 10 mg once daily (Chevrel 2006) <b>or</b> 70 mg once weekly (Shapiro 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131409\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131410\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &ge;35 mL/minute: No dosage adjustment  necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &lt;35 mL/minute: Use not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131411\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131381\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 70 mg/75 mL (75 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fosamax: 70 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 35 mg, 40 mg, 70 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Effervescent, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Binosto: 70 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131366\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11441253\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Binosto: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM318435.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WgPWVrnoP6kIShdNGV+r9fQ==&amp;TOPIC_ID=9427\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM318435.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Fosamax: http://www.merck.com/product/usa/pi_circulars/f/fosamax/fosamax_mg.pdf</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131385\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer first thing in the morning and &ge;30 minutes before the first food, beverage (except plain water), or other medication(s) of the day. Do not take with mineral water or with other beverages. Patients should be instructed to stay upright (not to lie down) for at least 30 minutes <b>and</b> until after first food of the day (to reduce esophageal irritation).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Administer oral solution, followed with at least 2 oz of plain water. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet (Fosamax): Must be taken with 6 to 8 oz of plain water. The tablet should be swallowed whole; do not chew or suck.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, effervescent (Binosto): Dissolve one tablet in 4 oz of room temperature plain water only; once effervescence stops, wait &ge;5 minutes and stir the solution for ~10 seconds and then drink.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131384\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Osteoporosis: </b>Treatment of osteoporosis in postmenopausal females (Fosamax, Binosto); prevention of osteoporosis in postmenopausal females (Fosamax); treatment of osteoporosis in males (Fosamax, Binosto); treatment of Paget disease of the bone in patients who are symptomatic, at risk for future complications, or with alkaline phosphatase &ge;2 times the upper limit of normal (Fosamax); treatment of glucocorticoid-induced osteoporosis in males and females with low bone mineral density who are receiving a daily dosage &ge;7.5 mg of prednisone (or equivalent) (Fosamax)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25816101\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Glucocorticoid-induced osteoporosis (prevention); Osteogenesis imperfecta (adults); Osteogenesis imperfecta (children/adolescents)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131431\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alendronate may be confused with risedronate</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fosamax may be confused with Flomax, Fosamax Plus D, fosinopril, Zithromax</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fosamax  [US, Canada, and multiple international markets] may be confused with Fisamox brand name for amoxicillin [Australia]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131373\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Incidence of adverse effects (mostly GI) increases significantly in patients treated for Paget's disease at 40 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">&gt;10%: Endocrine &amp; metabolic: Decreased serum calcium (18%; transient, mild) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Decreased serum phosphate (10%; transient, mild) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal pain (2% to 7%), acid regurgitation (1% to 5%), flatulence (&le;4%), gastroesophageal reflux disease (3%), constipation (&le;3%), diarrhea (&le;3%), dyspepsia (1% to 3%), nausea (1% to 3%), esophageal ulcer (2%), dysphagia (1%), melena (1%), abdominal distension (&le;1%), gastric ulcer (&le;1%; may be severe with complications), gastritis (&le;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Musculoskeletal pain (&le;6%; includes bone pain, joint pain, and muscle pain), muscle cramps (&le;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Alopecia, cholesteatoma, conjunctivitis, dizziness, duodenal ulcer (may be severe with complications), dysgeusia, episcleritis, erythema, erosive esophagitis, esophageal perforation, esophageal stenosis, esophageal ulcer, esophagitis, exacerbation of asthma, femur fracture (low-energy fractures, including subtrochanteric and diaphyseal), fever, hypersensitivity reaction (includes angioedema and urticaria), hypocalcemia (symptomatic), joint swelling, malaise, oropharyngeal ulcer; osteonecrosis of the jaw (generally associated with tooth extraction and/or local infection with delayed healing), peripheral edema, pruritus, scleritis, skin rash (occasionally with photosensitivity), Stevens-Johnson syndrome, toxic epidermal necrolysis, uveitis, vertigo, weakness </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131388\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to alendronate, other bisphosphonates, or any component of the formulation; hypocalcemia; abnormalities of the esophagus (eg, stricture, achalasia) which delay esophageal emptying; inability to stand or sit upright for at least 30 minutes; increased risk of aspiration (effervescent tablets; oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Renal insufficiency with creatinine clearance &lt;35 mL/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131370\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone fractures: Atypical femur fractures (AFF) have been reported in patients receiving bisphosphonates. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures; atypical femur fractures have also been reported in patients not taking bisphosphonates, and in patients receiving glucocorticoids. Patients receiving long-term (&gt;3 to 5 years) bisphosphonate therapy may be at an increased risk (Adler 2016; NOF [Cosman 2014]); however, benefits of therapy (when used for osteoporosis) generally outweigh absolute risk of AFF within the first 5 years of treatment (Adler 2016). Patients presenting with thigh or groin pain with a history of receiving bisphosphonates should be evaluated for femur fracture. Consider interrupting bisphosphonate therapy in patients who develop a femoral shaft fracture; assess for fracture in the contralateral limb.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone/joint/muscle pain: Severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal mucosa irritation: May cause irritation to upper gastrointestinal mucosa. Esophagitis, dysphagia, esophageal ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition). Discontinue use if new or worsening symptoms develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: Hypocalcemia has been reported with the use of bisphosphonates. Prior to therapy initiation, hypocalcemia must be corrected; ensure adequate calcium and vitamin D intake.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Conjunctivitis, uveitis, episcleritis, and scleritis have been reported with alendronate; patients presenting with signs of ocular inflammation may require further ophthalmologic evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving bisphosphonates. Known risk factors for MRONJ include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapy (eg, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, ill-fitting dentures, and comorbid disorders (anemia, coagulopathy, infection, preexisting dental or periodontal disease). Risk may increase with increased duration of bisphosphonate use. According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonate and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy; risk of MRONJ is significantly higher in cancer patients receiving antiresorptive therapy compared to patients receiving osteoporosis treatment (regardless of medication used or dosing schedule). MRONJ risk is also increased with intravenous antiresorptive use compared to the minimal risk associated with oral bisphosphonate use, although risk appears to increase with oral bisphosphonates when duration of therapy exceeds 4 years (AAOMS [Ruggiero 2014]). The manufacturer's labeling states that in patients requiring invasive dental procedures, discontinuing bisphosphonates may reduce the risk of ONJ and clinical judgment should guide the decision. However, the AAOMS suggests there is currently no evidence that interrupting oral bisphosphonate therapy alters the risk of ONJ following tooth extraction, and that in patients receiving oral bisphosphonates for &lt;4 years who have no clinical risk factors, no alternations or delay in any procedure common to oral/maxillofacial surgeons, periodontists, and other dental providers is necessary (special considerations apply to patients receiving dental implants). Conversely, in patients receiving oral bisphosphonates for &gt;4 years <b>or</b> in patients receiving oral bisphosphonates for &lt;4 years who have also taken corticosteroids or antiangiogenic medications concomitantly, the AAOMS recommends considering a 2-month, drug-free period prior to invasive dental procedures (recommendation based on a theoretical benefit). Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]). According to the manufacturer, discontinuation of the bisphosphonate therapy should be considered (based on risk/benefit evaluation) in patients who develop ONJ.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment (not recommended for use in patients with CrCl &lt;35 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effervescent tablet: Each effervescent tablet contains 650 mg of sodium (NaCl 1650 mg). Use with caution in patients following a sodium-restricted diet.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298701\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131375\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9427&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Magaldrate; Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: May enhance the adverse/toxic effect of Alendronate. Specifically, the incidence of upper gastrointestinal adverse events may be increased<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parathyroid Hormone: Alendronate may diminish the therapeutic effect of Parathyroid Hormone. More specifically, Alendronate may interfere with normalization of blood calcium concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131400\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">All food and beverages interfere with absorption. Coadministration with dairy products may decrease alendronate absorption. Beverages (especially orange juice, coffee, and mineral water) and food may reduce the absorption of alendronate as much as 60%. Management: Alendronate must be taken first thing in the morning and &ge;30 minutes before the first food, beverage (except plain water), or other medication of the day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131377\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131391\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. It is not known if bisphosphonates cross the placenta, but fetal exposure is expected (Djokanovic 2008; Stathopoulos 2011). Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by dose and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy; however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic 2008; Levy 2009; Stathopoulos 2011). Until additional data is available, most sources recommend discontinuing bisphosphonate therapy in women of reproductive potential as early as possible prior to a planned pregnancy; use in premenopausal women should be reserved for special circumstances when rapid bone loss is occurring (Bhalla 2010; Pereira 2012; Stathopoulos 2011). Because hypocalcemia has been described following in utero bisphosphonate exposure, exposed infants should be monitored for hypocalcemia after birth (Djokanovic 2008; Stathopoulos 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20471711\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if alendronate is excreted into breast milk. The manufacturer recommends that caution be exercised when administering alendronate to nursing women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131392\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Women and men should consume:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium: 1,000 mg/day (men: 50 to 70 years) <b>or</b> 1,200 mg/day (women &ge;51 years and men &ge;71 years) (IOM 2011; NOF [Cosman 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D: 800 to 1,000 int. units/day (men and women &ge;50 years) (NOF [Cosman 2014]). Recommended Dietary Allowance (RDA): 600 int. units daily (men and women &le;70 years) <b>or</b> 800 int. units/day (men and women &ge;71 years) (IOM 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131379\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Osteoporosis: Bone mineral density (BMD) should be evaluated 1 to 2 years after initiating therapy and every 1 to 2 years (or less frequently if stable) thereafter (AACE/ACE [Camacho 2016]; NOF [Cosman 2014]); in patients with combined alendronate and glucocorticoid treatment, evaluate BMD at initiation of glucocorticoid therapy and after 6 to 12 months, then every 2 to 3 years if patient continues to have significant osteoporosis risk factors (ACR [Buckley 2017]); annual measurements of height and weight, assessment of chronic back pain; serum calcium and 25(OH)D; may consider monitoring biochemical markers of bone turnover</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paget disease: Alkaline phosphatase at 6 to 12 weeks for initial response to treatment (when bone turnover will have shown a substantial decline) and potentially at 6 months (maximal suppression of high bone turnover); following treatment completion, monitor at ~6- to 12-month intervals (Singer 2014); monitoring more specific biochemical markers of bone turnover (eg, serum P1NP, NTX, serum beta-CTx) is generally only warranted in patients with Paget disease who have abnormal liver or biliary tract function or when early assessment of response to treatment is needed (eg, spinal compression, very active disease) (Singer 2014); pain; serum calcium and 25(OH)D</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131382\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium (total): Adults: 9.0 to 11.0 mg/dL (2.05 to 2.54 mmol/L), may slightly decrease with aging</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus: 2.5 to 4.5 mg/dL (0.81 to 1.45 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D: There is no clear consensus on a reference range for total serum 25(OH)D concentrations or the validity of this level as it relates clinically to bone health. In addition, there is significant variability in the reporting of serum 25(OH)D levels as a result of different assay types in use; however, the following ranges have been suggested:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults (IOM 2011): Sufficient levels in practically all persons: &ge;20 ng/mL (50 nmol/L); concern for risk of toxicity: &gt;50 ng/mL (125 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Osteoporosis patients (NOF [Cosman 2014]): Recommended level to reach and maintain: ~30 ng/mL (75 nmol/L) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131369\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A bisphosphonate which inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption, leading to an indirect increase in bone mineral density. In Paget's disease, characterized by disordered resorption and formation of bone, inhibition of resorption leads to an indirect decrease in bone formation; but the newly-formed bone has a more normal architecture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131387\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 28 L (exclusive of bone)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~78%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Fasting:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;4 years and Adolescents: Mean range: 0.41% to 0.56% (Nakhla 2011; Ward 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.6%; reduced up to 60% with coffee or orange juice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Exceeds 10 years</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine; feces (as unabsorbed drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131390\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Alendronate Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg/75 mL (75 mL): $57.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, effervescent</b> (Binosto Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg (1): $57.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Alendronate Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $292.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $87.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">35 mg (4): $81.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $197.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg (4): $81.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Fosamax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg (4): $153.41</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131393\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adronat (AU, IT, PT);</li>\n      <li>Albinax (VN);</li>\n      <li>Aldren 70 (PH, TH);</li>\n      <li>Aldron (HR);</li>\n      <li>Aldrox (CL);</li>\n      <li>Alenato (AR);</li>\n      <li>Alend (KR);</li>\n      <li>Alendomax (JO);</li>\n      <li>Alendovenir (IL);</li>\n      <li>Alendra (PH);</li>\n      <li>Alendrate (NZ);</li>\n      <li>Alendrex (NZ);</li>\n      <li>Alendro (AU, LK, SA);</li>\n      <li>Alendro Once Weekly (KW);</li>\n      <li>Alendrobell (AU);</li>\n      <li>Alendronate (TH);</li>\n      <li>Alendros (KR);</li>\n      <li>Alendroxl (PH);</li>\n      <li>Alenfos (KR);</li>\n      <li>Alenfosa (VN);</li>\n      <li>Allentop (HK);</li>\n      <li>Alnate (LK);</li>\n      <li>Alovell (ID, PH, VN);</li>\n      <li>Arendal (PE);</li>\n      <li>Armol (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Bifosa (IN);</li>\n      <li>Bisbon (KR);</li>\n      <li>Bonafide (LK);</li>\n      <li>Bonaid (KR);</li>\n      <li>Bonalon (JP);</li>\n      <li>Bonamax (QA);</li>\n      <li>Bonapex (EG);</li>\n      <li>Bonmax (JO);</li>\n      <li>BonMax (TH);</li>\n      <li>Calidron (JO);</li>\n      <li>Densate (AU);</li>\n      <li>Drate (LK);</li>\n      <li>Endronax (BR);</li>\n      <li>Fonat (AU);</li>\n      <li>Forosa (PH);</li>\n      <li>Fosalan (IL);</li>\n      <li>Fosamax (AE, AR, AT, AU, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CL, CN, CY, CZ, DE, DK, EC, EE, EG, ES, FI, FR, GB, GR, GY, HR, IE, IT, JM, JO, KR, KW, LB, LK, LU, MT, MX, NL, NO, NZ, PE, PK, PL, PR, PT, QA, RO, RU, SA, SE, SG, SI, SK, SR, TR, TT, TW, VE, VN);</li>\n      <li>Fosamax Once Weekly (AE, BH, HK, LB, SA);</li>\n      <li>Fosmin (EC, PE);</li>\n      <li>Fostepor (IE);</li>\n      <li>Fostolin (IE);</li>\n      <li>Fosval (PY);</li>\n      <li>Gendarin (SE);</li>\n      <li>Gubang (CN);</li>\n      <li>Kalosten (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Lendomax (AE);</li>\n      <li>Malend (KR);</li>\n      <li>Marvil (LB, PE, UY);</li>\n      <li>MaxiBone (IL);</li>\n      <li>MaxiBone 70 (IL);</li>\n      <li>Maxlen (TH);</li>\n      <li>Nichospor (ID);</li>\n      <li>Oseomax (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Oseotenk (AR);</li>\n      <li>Osficar (CO);</li>\n      <li>Ossmax (AU);</li>\n      <li>Osteo-Plus (PH);</li>\n      <li>Osteocor (PH);</li>\n      <li>Osteodron (PH);</li>\n      <li>Osteofar (ID);</li>\n      <li>Osteofos (HK, IN);</li>\n      <li>Osteol (PY);</li>\n      <li>Osteomax (PH);</li>\n      <li>Osteomel (IE);</li>\n      <li>Osteopor (UY);</li>\n      <li>Osteosan (CL);</li>\n      <li>Osteovan (CR);</li>\n      <li>Osteve (LB, QA);</li>\n      <li>Ostex (CO);</li>\n      <li>Osto (LK);</li>\n      <li>Porosal (VE);</li>\n      <li>Reventa (PH);</li>\n      <li>Romax (IE);</li>\n      <li>Tevanate (BG, TW);</li>\n      <li>Valora (HR);</li>\n      <li>Zeroclast (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research [published correction appears in <i>J Bone Miner Res</i>. 2016;31(10):1910]. <i>J Bone Miner Res</i>. 2016;31(1):16-35. doi: 10.1002/jbmr.2708.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/26350171/pubmed\" target=\"_blank\" id=\"26350171\">26350171</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Akcay T, Turan S, Guran T, Bereket A. Alendronate treatment in children with osteogenesis imperfecta. <i>Indian Pediatr</i>. 2008;45(2):105-109<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/18310788/pubmed\" target=\"_blank\" id=\"18310788\">18310788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alendronate sodium tablet [prescribing information]. Dayton, NJ: Aurobindo Pharma; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Dental Association Council on Scientific Affairs, &ldquo;Dental Management of Patients Receiving Oral Bisphosphonate Therapy,&rdquo; JADA, 2006, 137(8):1144-50. Available at http://jada.ada.org/article/S0002-8177(14)64960-6/pdf16873332</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Dental Association Council on Scientific Affairs, &ldquo;Dental Management of Patients Receiving Oral Bisphosphonate Therapy,&rdquo; JADA, 2006, 137(8):1144-50. Available at http://jada.ada.org/article/S0002-8177(14)64960-6/pdf16873332</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Author Unknown, &ldquo;Safety Update: Bone-Building Drugs: Risks Explained,&rdquo; <i>Consum Rep Health</i>, 2006, 18(5):3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhalla AK, &quot;Management of Osteoporosis in a Pre-menopausal Woman,&quot; <i>Best Pract Res Clin Rheumatol</i>, 2010, 24(3):313-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/20534366/pubmed\" target=\"_blank\" id=\"20534366\">20534366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Binosto (alendronate) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. <i>Arthritis Rheumatol</i>. 2017;69(8):1521-1537.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/28585373/pubmed\" target=\"_blank\" id=\"28585373\">28585373</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis&ndash;2016: executive summary [published correction appears in <i>Endocr Pract. </i>2017;23(3):383]. <i>Endocr Pract</i>. 2016;22(9):1111-1118. doi: 10.4158/EP161435.ESGL.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/27643923/pubmed\" target=\"_blank\" id=\"27643923\">27643923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cartsos VM, Zhu S, and Zavras AI, &ldquo;Bisphosphonate Use and the Risk of Adverse Jaw Outcomes: A Medical Claims Study of 714,217 People,&rdquo; <i>J Am Dent Assoc</i>, 2008, 139(1):23-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/18167381/pubmed\" target=\"_blank\" id=\"18167381\">18167381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chevrel G, Schott AM, Fontanges E, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. <i>J Bone Miner Res</i>. 2006;21(2):300-306<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/16418786/pubmed\" target=\"_blank\" id=\"16418786\">16418786</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chesnut CH 3rd, McClung MR, Ensrud KE, et al, &ldquo;Alendronate Treatment of the Postmenopausal Osteoporatic Woman: Effect of Multiple Dosages on Bone Mass and Bone Remodeling,&rdquo; <i>Am J Med</i>, 1995, 99(2):144-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/7625419/pubmed\" target=\"_blank\" id=\"7625419\">7625419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Christodoulou C, Pervena A, Klouvas G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. <i>Oncology.</i> 2009;76(3):209-211.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/19212145/pubmed\" target=\"_blank\" id=\"19212145\">19212145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi: 10.1007/s00198-014-2794-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/25182228/pubmed\" target=\"_blank\" id=\"25182228\">25182228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Djokanovic N, Klieger-Grossmann C, and Koren G, &quot;Does Treatment With Bisphosphonates Endanger the Human Pregnancy?&quot; <i>J Obstet Gynaecol Can</i>, 2008, 30(12):1146-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/19175968/pubmed\" target=\"_blank\" id=\"19175968\">19175968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durie BG, Katz M, and Crowley J, &quot;Osteonecrosis of the Jaw and Bisphosphonates,&quot; <i>N Engl J Med</i>, 2005, 353(1):99-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/16000365/pubmed\" target=\"_blank\" id=\"16000365\">16000365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edwards BJ, Hellstein JW, Jacobsen PL, et al, &ldquo;Updated Recommendations for Managing the Care of Patients Receiving Oral Bisphosphonate Therapy: An Advisory Statement From the American Dental Association Council on Scientific Affairs,&rdquo; <i> J Am Dent Assoc</i>, 2008, 139(12):1674-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/19047674/pubmed\" target=\"_blank\" id=\"19047674\">19047674</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Filleul O, Crompot E, and Saussez S, &quot;Bisphosphonate-Induced Osteonecrosis of the Jaw: A Review of 2,400 Patient Cases,&quot; <i>J Cancer Res Clin Oncol</i>, 2010, 136(8):1117-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/20508948/pubmed\" target=\"_blank\" id=\"20508948\">20508948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fosamax (alendronate) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fosamax (alendronate) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    French AE, Kaplan N, Lishner M, et al, &ldquo;Taking Bisphosphonates During Pregnancy,&rdquo; <i>Can Fam Physician</i>, 2003, 49:1281-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/14594094/pubmed\" target=\"_blank\" id=\"14594094\">14594094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hellstein JW, Adler RA, Edwards B, et al, &quot;Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Executive Summary of Recommendations From the American Dental Association Council on Scientific Affairs,&quot; <i>J Am Dent Assoc</i>, 2011, 142(11):1243-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/22041409/pubmed\" target=\"_blank\" id=\"22041409\">22041409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hellstein JW, Adler RA, Edwards B, et al, &quot;Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Recommendations From the American Dental Association Council on Scientific Affairs,&quot; 2011, Available at http://www.ada.org/~/media/ADA/Member%20Center/FIles/topics_ARONJ_report.ashx. Accessed February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D,</i> Washington, DC: The National Academies Press, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>J Bone Miner Res.</i> 2015; 30(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/25414052/pubmed\" target=\"_blank\" id=\"25414052\">25414052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy S, Fayez I, Taguchi N, et al, &quot;Pregnancy Outcome Following <i>in utero</i> Exposure to Bisphosphonates,&quot; <i>Bone</i>, 2009, 44(3):428-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/19059370/pubmed\" target=\"_blank\" id=\"19059370\">19059370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lo JC, O'Ryan FS, Gordon NP, et al, &ldquo;Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure,&rdquo; <i>J Oral Maxillofac Surg</i>, 2010, 68(2):243-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/19772941/pubmed\" target=\"_blank\" id=\"19772941\">19772941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of The North American Menopause Society,&rdquo; <i>Menopause</i>, 2010, 17(1):25-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/20061894/pubmed\" target=\"_blank\" id=\"20061894\">20061894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marx RE, Sawatari Y, Fortin M, et al, &ldquo;Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment,&rdquo; <i>J Oral Maxillofac Surg</i>, 2005, 63(11):1567-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/16243172/pubmed\" target=\"_blank\" id=\"16243172\">16243172</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mavrokokki T, Cheng A, Stein B, et al, &ldquo;Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia,&rdquo; <i>J Oral Maxillofac Surg</i>, 2007, 65(3):415-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/17307586/pubmed\" target=\"_blank\" id=\"17307586\">17307586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21962451\"></a>Nakhla M, Denker AE, Connor JD, et al. Bioavailability and short-term tolerability of alendronate in glucocorticoid-treated children. <i>Clin Ther. </i>2011;33(10):1516-1523.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/21962451/pubmed\" target=\"_blank\" id=\"21962451\">21962451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orwoll E, Ettinger M, Weiss S, et al, &ldquo;Alendronate for the Treatment of Osteoporosis in Men,&rdquo; <i>N Engl J Med</i>, 2000, 343(9):604-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/10979796/pubmed\" target=\"_blank\" id=\"10979796\">10979796</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pereira RM, Carvalho JF, Paula AP, et al, &quot;Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis,&quot; <i>Rev Bras Reumatol</i>, 2012, 52(4):580-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/22885424/pubmed\" target=\"_blank\" id=\"22885424\">22885424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pizones J, Plotkin H, Parra-Garcia JI, et al. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. <i>J Pediatr Orthop</i>. 2005;25(3):332-335<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/15832149/pubmed\" target=\"_blank\" id=\"15832149\">15832149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ralston SH, &ldquo;Pathogenesis of Paget's Disease of Bone,&rdquo; <i>Bone</i>, 2008, 43(5):819-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/18672105/pubmed\" target=\"_blank\" id=\"18672105\">18672105</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/25234529/pubmed\" target=\"_blank\" id=\"25234529\">25234529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero S, Gralow J, Marx RE, et al, &quot;Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer,&quot; <i>J Clin Oncol</i>, 2006, 2(1):7-14.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9682041\"></a>Saag KG, Emkey R, Schnitzer TJ, et al, Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis, Glucocorticoid-Induced Osteoporosis Intervention Study Group. <i>N Engl J Med</i>. 1998;339(5):292-299.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/9682041/pubmed\" target=\"_blank\" id=\"9682041\">9682041</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sellmeyer DE, &ldquo;Atypical Fractures as a Potential Complication of Long-term Bisphosphonate Therapy,&rdquo; <i>JAMA</i>, 2010, 304(13):1480-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/20924014/pubmed\" target=\"_blank\" id=\"20924014\">20924014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillen C. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. <i>Calcif Tissue Int</i>. 2010;87(2):120-129<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/20544187/pubmed\" target=\"_blank\" id=\"20544187\">20544187</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shane E, Burr D, Ebeling PR, et al, &ldquo;Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research,&rdquo; <i>J Bone Miner Res</i>, 2010, 25(11):2267-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/20842676/pubmed\" target=\"_blank\" id=\"20842676\">20842676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singer FR, Bone HG, Hosking DJ, et al. Paget's disease of bone: an Endocrine Society practice guideline. <i>J Clin Endocrinol Metab</i>. 2014;99(12):4408-4422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/25406796/pubmed\" target=\"_blank\" id=\"25406796\">25406796</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stathopoulos IP, Liakou CG, Katsalira A, et al, &quot;The Use of Bisphosphonates in Women Prior to or During Pregnancy and Lactation,&quot; <i>Hormones (Athens)'</i>, 2011, 10(4):280-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/22281884/pubmed\" target=\"_blank\" id=\"22281884\">22281884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21106710\"></a>Ward LM, Rauch F, Whyte MP, et al. Alendronate for the treatment of pediatric osteogenesis imperfect: a randomized placebo-controlled study. <i>J Clin Endocrinol Metab</i>. 2011;96(2):355-364.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/21106710/pubmed\" target=\"_blank\" id=\"21106710\">21106710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watts NB, &ldquo;Treatment of Osteoporosis With Bisphosphonates,&rdquo; <i>Rheum Dis Clin North Am</i>, 1994, 20(3):717-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/7984786/pubmed\" target=\"_blank\" id=\"7984786\">7984786</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Whyte MP, &ldquo;Clinical Practice. Paget's Disease of Bone,&rdquo; <i>N Engl J Med</i>, 2006, 355(6):593-600.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/16899779/pubmed\" target=\"_blank\" id=\"16899779\">16899779</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wysowski DK, &ldquo;Reports of Esophageal Cancer With Oral Bisphosphonate Use,&rdquo; <i>N Engl J Med</i>, 2009, 360(1):89-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-drug-information/abstract-text/19118315/pubmed\" target=\"_blank\" id=\"19118315\">19118315</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9427 Version 213.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F131404\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F131405\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F131424\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F131408\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F131409\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F131410\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F131411\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F131381\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F131366\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F11441253\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F131385\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F131384\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25816101\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F131431\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F131373\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F131388\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F131370\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298701\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F131375\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F131400\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F131377\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F131391\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20471711\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F131392\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F131379\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F131382\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F131369\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F131387\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F131390\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F131393\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9427|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=alendronate-patient-drug-information\" class=\"drug drug_patient\">Alendronate: Patient drug information</a></li><li><a href=\"topic.htm?path=alendronate-pediatric-drug-information\" class=\"drug drug_pediatric\">Alendronate: Pediatric drug information</a></li></ul></div></div>","javascript":null}